miRecule, Inc. is a pre-clinical biotechnology company focused on the development of RNA therapeutics to treat a variety of diseases. miRecule has developed DREAmiR, a genomics-based discovery platform that identifies critical RNA targets in specific subsets of patients that would benefit from treatment. The company then creates proprietary chemically-modified RNA therapeutics with improved pharmacology and utilizes antibodies for targeted delivery to the diseased tissue.
The startup is developing therapeutics for drug-resistant cancers — and applying its technology to other arenas, including Covid-19. Read the full story from the Washington Business Journal.
This has certainly been a year unlike any other for BioHealth Capital Region (BHCR) life science companies of all sizes and kinds. Just a few months into 2020, the coronavirus pandemic swept the…
Biotech company is developing breakthrough RNA therapies for cancer and muscular dystrophy